CT Volumetry Can Potentially Predict the Local Stage for Gastric Cancer after Chemotherapy

Zhi-Cong Wang,Chen Wang,Ying Ding,Yuan Ji,Meng-Su Zeng,Sheng-Xiang Rao

DOI: https://doi.org/10.5152/dir.2017.16517

2017-01-01

Diagnostic and Interventional Radiology

Abstract:PURPOSE We aimed to evaluate the value of CT tumor volumetry for predicting T and N stages of gastric cancer after chemotherapy, with pathologic results as the reference standard.METHODS This study retrospectively evaluated 42 patients diagnosed with gastric cancer, who underwent chemotherapy followed by surgery. Pre- and post-treatment CT tumor volumes (VT) were measured in portal venous phase and volume reduction ratios were calculated. Correlations between pre- and post-treatment VT, reduction ratio, and pathologic stages were analyzed. Receiver operator characteristic (ROC) analyses were also performed to assess diagnostic performance for prediction of downstaging to T0-2 stage and N0 stage.RESULTS Pretreatment VT, post-treatment VT, and VT reduction ratio were significantly correlated with T stage (r(s)=0.329, r(s)=0.546, r(s)= -0.422, respectively). Post-treatment VT and VT reduction ratio were significantly correlated with N stage (r(s)=0.442 and r(s)= -0.376, respectively). Pretreatment VT, post-treatment VT, and VT reduction ratio were significantly different between T0-2 and T3,4 stage tumors (P = 0.05, P < 0.001, and P = 0.002, respectively). The differences between N0 and >= N1 groups were also statistically significant (P = 0.005 for post-treatment V-T, P = 0.016 for V-T reduction ratio, respectively). The area under the ROC curve (AUC) for identification of T0-2 groups was 0.70 for pretreatment V-T, 0.88 for post-treatment V-T, and 0.82 for V-T reduction ratio, respectively. AUC was 0.78 for post-treatment V-T and 0.74 for V-T reduction ratio for identification of N0 groups.CONCLUSION CT tumor volumetry, particularly post-treatment measurement of V-T, is potentially valuable for predicting histopathologic T and N stages after chemotherapy in patients with gastric cancer.